London · Delayed Price · Currency is GBP · Price in USD Palatin Technologies Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY2026 saw a significant revenue boost from licensing, improved net loss, and a strong cash position. Lead obesity therapies are advancing, with IND submissions planned for late 2026 and early 2027, supported by strategic partnerships and a focus on best-in-class selectivity.
-
Advanced rare obesity pipeline with strengthened finances from a public offering and asset sub-licensing. Cash runway extends beyond March 2027, with key clinical milestones ahead and reduced operating expenses expected next quarter.
-
Secured major collaboration and milestone payments, completed $18.2M equity offering, and regained NYSE American listing. Q1 saw $8.8M in revenue and a $4.7M net income, with a strong cash runway projected into 2026.
Fiscal Year 2025
-
Positive phase II and III clinical results in obesity, ulcerative colitis, and dry eye disease support ongoing business development and outlicensing efforts. Operating expenses and net loss decreased year-over-year, while the company addresses NYSE delisting and seeks additional funding.
-
No product sales this quarter after the Vyleesi divestiture; net loss narrowed to $2.4M. Multiple clinical programs in obesity, ulcerative colitis, and kidney disease are advancing, with key data readouts expected soon.
-
Revenue dropped to zero after the Vyleesi sale, with a higher net loss and lower cash balance. Focus is now on advancing obesity programs, with key clinical data expected in early 2025 and active outlicensing discussions for non-core assets.
Fiscal Year 2024
-
Fiscal 2024 saw a major asset sale, reduced operating expenses, and a net loss of $29.7 million. Pipeline programs in ocular, obesity, and sexual dysfunction advanced, with key clinical milestones and funding efforts underway.